DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

To join the DETERMINE trial, your doctor will first check if you meet certain requirements. You must have a cancer that has been proven by a biopsy, whether it's a solid tumour (like in an organ) or a blood cancer. Importantly, your cancer should have a specific genetic change (mutation) that the trial is looking for, which would have been found through special testing.

This trial is for people who have already tried standard treatments or for whom there aren't any effective standard treatments available, and whose cancer has continued to grow or come back. The good news is that the trial is open to adults, teenagers, and children. You should also generally be well enough to take part, with a life expectancy of at least three months.

Finally, you or your parent/guardian (if you are under 16) would need to agree to take part and give your written permission. You'd also need to be able to cooperate with the treatment plan and follow-up appointments. Some specific additional checks might be needed depending on the particular medicine being tested.

If you join the DETERMINE trial, you will be given one of the study medicines. This medicine is already approved for other uses, but this trial is testing it in a new way. You will have regular visits to the hospital or clinic to check how you are doing, how the medicine is working, and if you have any side effects. These visits will likely include physical exams, blood tests, and scans to monitor your cancer. Before you start, you'll need to provide a new tissue sample (biopsy) and blood samples for research purposes. The duration of your participation will depend on how you respond to the treatment and the specific 'arm' of the trial you are in, but the doctors will discuss this with you fully.